Status:

COMPLETED

Radiation Therapy and Combination Chemotherapy With or Without Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed By Surgery

Lead Sponsor:

Federation Francophone de Cancerologie Digestive

Conditions:

Esophageal Cancer

Eligibility:

All Genders

Phase:

PHASE3

Brief Summary

RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as fluorouracil and cisplatin, work in different ways to stop the growth of tumor cells, eith...

Detailed Description

OBJECTIVES: * Compare the survival of patients with locally advanced esophageal cancer treated with neoadjuvant radiotherapy and chemotherapy comprising fluorouracil and cisplatin followed by surgery...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed epidermoid or glandular cancer of the esophagus meeting the following criteria:
  • Tumor volume with or without mediastinal adenopathy, celiac, or subclavicular involvement
  • T3, N0-N1 disease
  • Tumor extends into fifth stratum by endosonographic scan
  • Resectable disease (palliative or curative)
  • No cervical tumor
  • No T1, T2, or T4 tumors
  • No tracheo-esophageal fistula or tracheal invasion
  • No gastric cardia cancer by gastroscopy
  • No visceral (e.g., lung, bone, brain, liver), ganglion, or clavicular metastases
  • PATIENT CHARACTERISTICS:
  • WHO performance status 0-2
  • Creatinine normal
  • WBC ≥ 3,000/mm\^3
  • Neutrophil count ≥ 1,500/mm\^3
  • Platelet count ≥ 100,000/mm\^3
  • Transaminases ≥ 60%
  • Bilirubin ≤ 2.0 mg/dL
  • No cirrhosis
  • DLCO ≥ 1.5 L with or without hypoxemia at rest
  • No progressive coronary insufficiency
  • Weight loss ≤ 15%
  • No other malignancy in the past 2 years
  • Must be able to maintain sufficient enteral nutrition (2,000 calories/day)
  • Laser photodestruction, dilation, or gastric balloon allowed
  • No contraindication to radiotherapy
  • No recurring left paralysis
  • PRIOR CONCURRENT THERAPY:
  • No concurrent nephrotoxic or myelotoxic drugs

Exclusion

    Key Trial Info

    Start Date :

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    April 1 2007

    Estimated Enrollment :

    40 Patients enrolled

    Trial Details

    Trial ID

    NCT00416858

    End Date

    April 1 2007

    Last Update

    March 4 2014

    Active Locations (0)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 0 (0 locations)

    No Results Found

    We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.